Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
Information source: University of Pittsburgh
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Migraine
Intervention: eletriptan (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s):
Dawn Marcus, MD, Principal Investigator, Affiliation: University of Pittsburgh
Overall contact:
Denise McCarthy, Phone: 412-692-2856
Summary
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
Clinical Details
Official title: Assessment and Prevention of Menstrual Migraine: Phase 1-Prospective Survey of Self-Identified Menstrual Migraine. Phase 2-Prevention of Menstrual Migraine With Relpax
Study design: Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Change in headache index
Detailed description:
Women are followed prospectively for 3 months, recording headaches, other symptoms, and
menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan
for 3 months.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- age 18-45 healthy menstruating female
Exclusion Criteria:
- cardiac or other conditions precluding use of eletriptan
Locations and Contacts
Denise McCarthy, Phone: 412-692-2856
University of Pittsburgh, Pittsburgh, Pennsylvania 15206, United States; Recruiting
Dawn Marcus, MD, Phone: 412-953-4797
Dawn Marcus, MD, Principal Investigator
Additional Information
Starting date: August 2004
Last updated: April 17, 2007
|
